Commonwealth Equity Services LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 13.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 143,774 shares of the company's stock after buying an additional 16,741 shares during the period. Commonwealth Equity Services LLC's holdings in Zoetis were worth $24,713,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. American National Bank boosted its position in Zoetis by 469.2% in the second quarter. American National Bank now owns 148 shares of the company's stock worth $25,000 after purchasing an additional 122 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company's stock worth $26,000 after purchasing an additional 112 shares during the last quarter. Worth Asset Management LLC purchased a new position in Zoetis in the first quarter worth $26,000. Financial Management Professionals Inc. boosted its position in Zoetis by 117.4% in the first quarter. Financial Management Professionals Inc. now owns 150 shares of the company's stock worth $28,000 after purchasing an additional 81 shares during the last quarter. Finally, Hanson & Doremus Investment Management boosted its position in Zoetis by 713.6% in the first quarter. Hanson & Doremus Investment Management now owns 179 shares of the company's stock worth $34,000 after purchasing an additional 157 shares during the last quarter. Hedge funds and other institutional investors own 91.05% of the company's stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 2,167 shares of the company's stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,269,818.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Roxanne Lagano sold 2,167 shares of the company's stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,269,818.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kristin C. Peck sold 9,689 shares of the company's stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the completion of the transaction, the chief executive officer now owns 39,743 shares of the company's stock, valued at $7,153,740. The disclosure for this sale can be found here. In the last three months, insiders sold 12,167 shares of company stock worth $2,190,623. 0.12% of the stock is currently owned by corporate insiders.

Zoetis Price Performance

Zoetis (NYSE:ZTS – Get Rating) last announced its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.22 by ($0.02). The business had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a return on equity of 49.03% and a net margin of 26.14%. Zoetis's revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.19 earnings per share. As a group, equities analysts anticipate that Zoetis Inc. will post 4.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on ZTS shares. Stifel Nicolaus lowered their target price on Zoetis from $275.00 to $225.00 and set a "buy" rating on the stock in a research note on Friday, June 24th. The Goldman Sachs Group decreased their price objective on Zoetis from $208.00 to $202.00 and set a "buy" rating on the stock in a research note on Thursday, July 21st. StockNews.com lowered Zoetis from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Piper Sandler began coverage on Zoetis in a research note on Monday, July 11th. They set an "overweight" rating and a $205.00 price objective on the stock. Finally, William Blair reiterated an "outperform" rating on shares of Zoetis in a research note on Friday, August 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $224.00.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading

• Get a free copy of the StockNews.com research report on Zoetis (ZTS)
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30
• This Is A Memorable Time To Buy Into Micron Technology
• How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
• Thor Industries Hammers Out A Bottom

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.